US 12,180,501 B2 · Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer

Abstract

Chimpanzee adenovirus (ChAd) and MVA virus vectors containing polynucleotide sequences encoding cancer antigens are administered sequentially to a subject in a suitable adjuvant in order to achieve a prime boost effect. The polynucleotides are expressed in situ following administration to provide a MAGEA3/linker/NY-ESO-1 fusion protein and variants thereof. Also, a hli/MAGEA3/linker/NY-ESO-1 fusion protein and variants thereof. An improved T cell response is found. In a particular synergistic therapeutic approach a triple combination of ChAdOx and MVA vectors together with chemotherapeutic agent and checkpoint inhibitor results in depleted myeloid derived suppressor cells (MDSC) and dramatically improves survival time in a mouse model of cancer.

Claims28

Dependent claims

A chimpanzee adenovirus (ChAd) vector or a modified vaccinia virus Ankara (MVA) vector encapsidating a nucleic acid molecule, the nucleic acid molecule comprising a polynucleotide sequence encoding (a) (i) a MAGE cancer antigen and/or NY-ESO-1 cancer antigen, or immunogenic fragments thereof;

or (ii) a MAGE cancer antigen and/or LAGE1 cancer antigen, or immunogenic fragments thereof;
and (b) a linker of between 5 and 9 amino acids which when expressed links the MAGE and NY-ESO-1, or MAGE and LAGE1 cancer antigens or fragments thereof, in either order, as a fusion protein, the polynucleotide sequence operably linked to expression control sequences which direct the translation, transcription and/or expression of the cancer antigen or fragment thereof in an animal cell as a fusion protein.

Dependencies are inferred from the claim text.

Facts

Application

17/250,561Filed 30 Jul 2019

Priority

GB 18126473 Aug 2018

Published

US 2021/0171981 A110 Jun 2021

Granted

31 Dec 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

C12N 15/86
For animal cells: viral vectors
A61K 39/00118
Cancer antigens: from embryonic or fetal origin
A61K 39/001186
Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE: mage
A61K 39/001188
Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE: ny-eso

Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer

Life of this patent

Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer

Life of this patent

Abstract

Claims28